Abstracts tagged "Rheumatoid Factor"

Abstract Number: 2607 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke
Raymundo Vera-Pineda¹, Alberto Cardenas-de La Garza², Jorge Esquivel-Valerio³, Dionicio A. Galarza-Delgado², Jose Ramon Azpiri-Lopez⁴, Iris J. Colunga-Pedraza², Mario Alberto Garza-Elizondo² and Jesus Zacarias Villarreal-Pérez⁵, ¹Cardiology., Hospital Universitario, UANL., Monterrey, Mexico, ²Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ³Rheumatology, Hospital Universitario.UANL, Monterrey, Mexico, ⁴Cardiology, Hospital Universitario, UANL., Monterrey, Mexico, ⁵Endocrinology, Hospital Universitario, UANL., Monterrey, Mexico
Background/Purpose: Tobacco smoke has been associated to anti-cyclic citrullinated peptide (anti-CCP) antibodies positivity. Recently, in wood-smoke-induced chronic obstructive pulmonary disease (COPD) patients without rheumatoid arthritis…
Abstract Number: 515 • 2015 ACR/ARHP Annual Meeting
Are Changes in Autoantibody Levels Reflecting Change in Prognosis of Rheumatoid Arthritis?
Manuel Unger¹, Farideh Alasti¹, Paul Studenic¹, Josef S. Smolen^2,3 and Daniel Aletaha¹, ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ³Department of Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria
Background/Purpose: The presence of rheumatoid factor (RF) and antibodies against citrullinated peptides (ACPA) is associated with progression of joint damage in patients with rheumatoid arthritis…
Abstract Number: 2660 • 2015 ACR/ARHP Annual Meeting
Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients
Nathalie Carrier¹, Anthony Marotta², Artur de Brum-Fernandes^3,4, Patrick Liang^3,4, Ariel Masetto^5,6, Yuan Gui², Jane Savill², Sara Michienzi², Henri Ménard⁷, Walter Maksymowych⁸ and Gilles Boire⁴, ¹Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ²Augurex Life Sciences Corp., Vancouver, BC, Canada, ³Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁵Department of Medicine/Division of Rheumatology, Université de Sherbrooke, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ⁶Department of Medicine/Division of Rheumatology, University of Sherbrooke, Sherbrooke, QC, Canada, ⁷MSK Research Axis, McGill University Health Center Research Institute, Montreal, QC, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada
Background/Purpose: The 14-3-3 family of conserved regulatory proteins consists of seven isoforms: α/β, γ, δ/ζ, ε, η, θ/τ and σ. These proteins exist as intracellular…
Abstract Number: 551 • 2015 ACR/ARHP Annual Meeting
Baseline Autoantibodies Preferentially Impact Abatacept Efficacy in Patients with RA Who Are Biologic Naïve: 6-Month Results from a Real-World, International, Prospective Study
R Alten¹, HG Nüßlein², M Galeazzi³, H-M Lorenz⁴, X Mariette⁵, A Cantagrel⁶, M Chartier⁷, G Desachy⁸, C Poncet⁹, C Rauch¹⁰ and M Le Bars¹¹, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Erlangen, Nürnberg, Germany, ³University of Siena, Siena, Italy, ⁴University Hospital, Heidelberg, Germany, ⁵Université Paris-Sud, Paris, France, ⁶Purpan Hospital, Toulouse, France, ⁷Chiltern International, Neuilly, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Docs International, Nanterre, France, ¹⁰Bristol-Myers Squibb, Munich, Germany, ¹¹Bristol-Myers Squibb, Rueil-Malmaison, France
Background/Purpose: In a recent meta-analysis, neither rheumatoid factor (RF) nor anti-cyclic citrullinated peptide (anti-CCP) antibody status were associated with clinical response to treatment with anti-TNF…
Abstract Number: 2676 • 2015 ACR/ARHP Annual Meeting
Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective
Alejandro Garza-Alpirez¹, Mario Alberto Garza-Elizondo², David Vega-Morales², Cassandra Skinner-Taylor², Ricardo Ramírez³, Roberto Negrete-López⁴, Jorge Esquivel-Valerio², Miguel Villarreal-Alarcon² and Andrés Mendiola¹, ¹Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario " Dr. José Eleuterio González". Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, Mexico, ³Rheumatology, Hospital Universitario, UANL., Monterrey, Mexico, ⁴Servicio de Reumatología, Departamento de Medicina Interna del Hospital Universitario, Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) diagnosis includes determination of autoantibodies and, their presence can represents 33% (2/6) to 50% (3/6) of the 2010 ACR/EULAR classification criteria…
Abstract Number: 584 • 2015 ACR/ARHP Annual Meeting
Positivity for Rheumatoid Factor Is Associated with a Better Short-Term Response and Long-Term Drug Retention of Abatacept: Results from Consecutive 508 Patients with Rheumatoid Arthritis in a Japanese Multicenter Registry
Nobunori Takahashi¹, Toshihisa Kojima¹, Koji Funahashi² and Naoki Ishiguro³, ¹Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ²Nagoya University Hospital, Nagoya, Japan, ³Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Abatacept (ABT) is a biologic drug and has been available for rheumatoid arthritis (RA) patients since 2010 in Japan. There have still been few…
Abstract Number: 623 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Characterized By a Lower Prevalence of B-Cell Related Clinical Manifestations and a Lower Biologic Systemic Activity
Luca Quartuccio¹, Chiara Baldini^2,3,4, Elena Bartoloni Bocci⁵, Roberta Priori⁶, Francesco Carubbi⁷, Laura Corazza¹, Alessia Alunno⁸, Serena Colafrancesco⁶, Nicoletta Luciano², Roberto Gerli⁹, Roberto Giacomelli¹⁰, Guido Valesini¹¹, Stefano Bombardieri¹² and Salvatore De Vita^13,14, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Internal Medicine, University of Pisa, Pisa, Italy, ³University of Pisa, Rheumatology Unit, Pisa, Italy, ⁴Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Medicine, University of Perugia, Pila, Italy, ⁶Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁷Rheumatology Clinic, University of L'Aquila, L'Aquila, Italy, ⁸Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁹Rheumatology Clinic, University of Perugia, Perugia, Italy, ¹⁰University of L'Aquila, L'Aquila, Italy, ¹¹Internal Medicine and Medical Specialties Department, Policlinico Umberto I, La Sapienza University of Rome, Roma, Italy, ¹²Rheumatology Unit, University of Pisa, Italy, Pisa, Italy, ¹³Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy, ¹⁴Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy
Background/Purpose: The American-European Consensus Group (AECG) Criteria (1) for Sjögren's syndrome (SS) require the presence of at least one of the following two conditions: the…
Abstract Number: 626 • 2015 ACR/ARHP Annual Meeting
Efficacy of Belimumab and Targeting of Rheumatoid Factor Positive B-Cells in Sjögren’s Syndrome: Follow-up of the Open-Label Phase II Study
Luca Quartuccio¹, Sara Salvin², Laura Corazza¹, Saviana Gandolfo², Martina Fabris³ and Salvatore De Vita⁴, ¹S. Maria della Misericordia, University of Udine, Italy, Udine, Italy, ²Rheumatology Clinic, University of Udine, Udine, Italy, ³Clinic of Rheumatology, University of Udine, Udine, Italy, ⁴Santa Maria della Misericordia Hospital, University of Udine, Udine, Italy
Background/Purpose: Belimumab, a monoclonal anti-B lymphocyte Stimulator (BLyS) antibody is preliminary found to be effective in Sjögren’s syndrome (SS) patients with moderate to high systemic…
Abstract Number: 1207 • 2015 ACR/ARHP Annual Meeting
Predictive Utility of Anti- Citrullinated Peptide Antibodies and Rheumatoid Factor – a Retrospective Dataanalysis
Miriam Gärtner, Mathias Schneeweiss, Josef S. Smolen and Klaus Machold, Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Antibody profiling encompassing rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) supports diagnosis in patients with Rheumatoid arthritis (RA). However, RF and ACPA are…
Abstract Number: 1559 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Medication Use Among Arab Patients with Rheumatoid Arthritis in Some Arab States
Karim Bayoumy¹, Soha Roger Dargham¹, Wessam Elhaq¹, Samar Al Emadi², Mohammed Hammoudeh², Basel Masri³, Hussein Halabi⁴, Humeira Badsha⁵, Imad Uthman⁶, Salah Mahdy², Robert Plenge⁷, Richa Saxena⁷, Marianthi Kapiri¹ and Thurayya Arayssi⁸, ¹Weill Cornell Medical College in Qatar, Doha, Qatar, ²Medicine, Hamad Medical Corporation, Doha, Qatar, ³Jordan Hospital, Amman, Jordan, ⁴Medicine, King Faisal Specialist Hospital and research center, Jeddah, Saudi Arabia, ⁵Al Biraa Arthritis and Bone Clinic, Dubai, United Arab Emirates, ⁶Internal Medicine, American University of Beirut, Beirut, Lebanon, ⁷The Broad Institute of MIT and Harvard, Program of Medical and Population Genetics, Cambridge, MA, ⁸Internal Medicine, Weill Cornell Medical College in Qatar, Doha, Qatar
Background/Purpose: Data on the clinical and genetic characteristics of Arab patients with Rheumatoid Arthritis (RA) is limited. Our aim is to report on the clinical…
Abstract Number: 1578 • 2015 ACR/ARHP Annual Meeting
Serum Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Are Associated with Subclinical Interstitial Lung Disease in the Multi-Ethnic Study of Atherosclerosis: A Population-Based Study
Elana J. Bernstein¹, R. Graham Barr², John H.M. Austin³, Steven M. Kawut⁴, Ganesh Raghu⁵, Jessica L. Sell⁶, Eric A. Hoffman⁷, John D. Newell Jr.⁸, Jubal R. Watts Jr.⁹, P. Hrudaya Nath¹⁰, Sushil K. Sonavane⁹, Joan M. Bathon¹, Darcy S. Majka¹¹ and David J. Lederer², ¹Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY, ²Medicine, Columbia University College of Physicians & Surgeons, New York, NY, ³Radiology, Columbia University College of Physicians & Surgeons, New York, NY, ⁴Division of Pulmonary, Allergy, and Critical Care, University of Pennsylvania, Philadelphia, PA, ⁵University of Washington, Seattle, WA, ⁶Columbia University College of Physicians & Surgeons, New York, NY, ⁷University of Iowa, Iowa City, IA, ⁸Radiology, University of Iowa, Iowa City, IA, ⁹Radiology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰University of Alabama at Birmingham, Birmingham, AL, ¹¹Division of Rheumatology, Northwestern University, Chicago, IL
Background/Purpose: Approximately 30% of adults diagnosed with interstitial lung disease (ILD) have an underlying established autoimmune disease. Based on the strong links between autoimmunity and…
Abstract Number: 1607 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Is Associated with the Distribution of Hand Joint Destruction in a Dose-Dependent Manner
Chikashi Terao¹, Noriyuki Yamakawa², Koichiro Yano³, I.M. Markusse⁴, Katsunori Ikari³, Shinji Yoshida³, Moritoshi Furu⁵, Motomu Hashimoto⁵, Hiromu Ito⁵, Takao Fujii⁶, Koichiro Ohmura⁷, Kosaku Murakami⁷, Meiko Takahashi², Masahide Hamaguchi⁸, Yasuharu Tabara², Atsuo Taniguchi³, Shigeki Momohara³, Soumya Raychaudhuri⁹, Cornelia F. Allaart¹⁰, Hisashi Yamanaka¹¹, Tsuneyo Mimori¹² and Fumihiko Matsuda¹³, ¹Departments of Genetics and Rheumatology, Brigham and Women's Hospital, Boston, MA, ²Kyoto University Graduate School of Medicine, Kyoto, Japan, ³Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁴LUMC, Leiden, Netherlands, ⁵Department of the Control for Rheumatic Diseases, Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁶Dept of Rheum/Clinical Immun, Kyoto University Graduate School of Medicine, Kyoto, Japan, ⁷Dept of Rheum & Clinical Immun, Kyoto Univ Grad School of Med, Kyoto, Japan, ⁸Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan, ⁹Arthritis Research UK Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ¹⁰Rheumatology, LUMC, Leiden, Netherlands, ¹¹Tokyo Women's Medical University, Tokyo, Japan, ¹²Dept of Rheum & Clinical Immun, Kyoto Univ Grad Schl of Med, Kyoto, Japan, ¹³Genomic Center, Kyoto University Graduate School of Medicine, Kyoto, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease leading to joint destruction. Although many studies have addressed correlates associated with the speed of joint destruction,…
Abstract Number: 1658 • 2015 ACR/ARHP Annual Meeting
Rheumatoid Factor Status Affects the Efficacy of First Biological Treatment in RA
Yoshikazu Ogawa¹, Nobunori Takahashi², Koji Funahashi², Shuji Asai³, Toki Takemoto³, Tatsuo Watanabe³, Nobuyuki Asai², Naoki Ishiguro⁴ and Toshihisa Kojima², ¹orthopedic surgery, Nagoya University Hospital, Nagoya, Japan, ²Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, ³Nagoya University Hospital, Nagoya, Japan, ⁴Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan
Background/Purpose: Rheumatoid factor (RF) is considered an important factor in diagnosing rheumatoid arthritis (RA). The association between the treatment efficacy of biological agents and RF…
Abstract Number: 1740 • 2015 ACR/ARHP Annual Meeting
Anti-Cyclic Citrullinated Peptide Antibodies and Inflammatory Bowel Disease
Jaita Mukherjee¹, Maria Mouyis¹, Kavina Shah¹, Mohammad Mahdi Saeidinejad¹, Ayesha Akbar² and Shahir Hamdulay¹, ¹Rheumatology, Northwick Park Hospital, Middlesex, United Kingdom, ²Gastroenterology, Northwick Park Hospital, Middlesex, United Kingdom
Background/Purpose: Enteropathic arthropathy refers to the pattern of inflammatory arthritis seen in association with gastrointestinal pathology. Arthritis in the presence of inflammatory bowel disease can…
Abstract Number: 2257 • 2015 ACR/ARHP Annual Meeting
Decline of Lung Function Is Associated with the Presence of Rheumatoid Factor in Korean Health Screening Subjects without Clinically Apparent Lung Diseases
Jiwon Hwang¹, Jae-Uk Song², Hyungjin Kim³, Hyemin Jeong⁴, Yeong Hee Eun⁵, Chan Hong Jeon⁶, Ji-Min Oh⁷, Jaejoon Lee⁴, Hoon-Suk Cha⁸, Eun-Mi Koh⁵ and Joong Kyong Ahn⁹, ¹Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, ²Department of Internal Medicine, Kangbuk Samsung Hospital, Seoul, South Korea, ³Department of medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁵Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁶Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, South Korea, ⁷Anyang SAM Hospital, Anyang, South Korea, ⁸Division of Rheumatology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc component of IgG. It is present in approximately 70-80% of rheumatoid arthritis (RA) patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].